Cytocompatibility of MG-63 osteosarcoma cells on chitosan/hydroxyapatite/lignin hybrid composite scaffoldin vitro

This study aims at fabricating promising cytocompatible hybrid biocomposite scaffolds from chitosan (CS), hydroxyapatite (HAP) and lignin (L) for bone tissue engineering by using freeze-drying technique. Different ratios of HAP to L (50:0, 37.5:12.5, 25:25 and 12.5:37.5) were taken to determine the optimum ratio for obtaining a composite with superior properties. The mechanical and biological properties of the resulting composites were investigated. The mechanical results showed that the prepared composite with a ratio of 25:25 of HAP/L exhibited a remarkable enhancement in the mechanical properties compared to the others. Additionally, it was found from thein vitroresults that the addition of L enhanced the water uptake value of the resulting scaffolds indicating their increased hydrophilicity. As a result, a significant increase in the attachment and proliferation of MG-63 cell line (osteoblast like cells) was observed in composite scaffolds with L over the scaffold without L (CS/HAP). From these results, it could be suggested that the prepared composite scaffold with 25:25 of HAP/L is very promising biomaterials in bone tissue-engineering as it exhibited a better mechanical and biological properties than the other prepared composites.

Evaluation of PEEK-TiO2- SiO2 nanocomposite as biomedical implants with regard to in-vitro biocompatibility and material characterization

Polyether Ether Ketone (PEEK) exhibits superior mechanical and biological safety characteristics, and its biological inertness significantly restricts its applicability in biomedical applications. Recent researches included active ceramic particles to enhance biological activity and broaden the application range of bioactive composites in medical implants. During the current investigation, acrylic acid-functionalized ceramic TiO₂ and SiO₂ nanoparticles (NP) were used to reinforce the PEEK matrix. The PEEK/TiO₂/SiO₂ (PTS) nanocomposite was fabricated using plastic injection moulding process. Different functional groups and crystal plane orientations of the composite were found through FTIR and XRD. The morphological and elemental analysis were carried out using FESEM and the EDAX mapping technique. The thermal stability of the composite was investigated through TGA and DSC analysis. The mean diameter of the inhibition zone of PTS polymer composite is 18.125 mm and 16.375 mm against E. coli and B. subtilis, respectively, which is higher than that of the mean diameter of the inhibition zone of PEEK. In-vitro direct and indirect cytotoxicity studies were carried using the MG-63 cell line and found the cell viability as 94.30% and cytotoxicity as 5.70% on PTS nanocomposite. Cell adhesion study was carried out using MG-63 cell line on the composite surface. That demonstrated the good cell adherence and cell proliferation those were observed through SEM morphologies. Thus, the newly developed composite serves as a potential candidate in biomedical applications.

In vitro selection of DNA aptamers against human osteosarcoma

BACKGROUND

 Osteosarcoma is a highly malignant bone tumor, most frequently occurring in the rapid bone growth phase. Effective treatment of this disease is hindered by the lack of specific probes for early diagnosis and the fast cancer widespread.

METHODS

 To find such probes, the cell-Systematic Evolution of Ligands by EXponential enrichment (cell-SELEX) methodology was implemented against the human osteosarcoma MG-63 cell line towards the selection of new specific aptamers. After 10 rounds of selection, the aptamer DNA pool was Sanger sequenced and the sequences were subjected to a bioinformatic analysis that included sequence alignment, phylogenetic relationship, and secondary structure prediction.

RESULTS

 A DNA aptamer (OS-7.9), with a dissociation constant (K_d) value in the nanomolar range (12.8 ± 0.9 nM), revealed high affinity against the target cells at the physiological temperature. Furthermore, the selected aptamer also recognized lung carcinoma and colon colorectal adenocarcinoma cell lines, which are reported as common metastasis sites of osteosarcoma.

CONCLUSIONS

 These results suggest that OS-7.9 could recognize a common protein expressed in these cancer cells, possibly becoming a potential molecular probe for early diagnosis and targeted therapies for metastatic disease. Moreover, to the best of our knowledge, this was the first attempt to generate a DNA aptamer (OS-7.9 aptamer) against the MG-63-cell line by cell-SELEX.

The inhibitory effects of cisplatin-radiation combination treatment on malignant osteosarcoma MG-63 cells and BRCA1-p53 pathways are more efficient than single treatments

The poor prognosis of patients with osteosarcoma remains a persistent problem, in particular for patients with unresectable tumors or metastasis. Therefore, combination of radiotherapy and chemotherapy has been considered for patients with metastasis or recurrence, patients unsuitable for surgery and patients refusing surgery. The present study aimed to investigate the effect of the combined treatment with cisplatin and radiation therapy on the biological characteristics of the osteosarcoma cell line MG-63 and the breast cancer 1 (BRCA1)-associated signaling pathways. Cell proliferation was determined using Cell Counting kit-8 assay, and cell apoptosis and cell cycle were assessed by flow cytometry. Cell migration was examined by Transwell assay. The mRNA and protein expression levels of candidate genes, including BRCA1 and p53, were determined by reverse transcription-quantitative PCR and western blotting, respectively. The results demonstrated that combined treatment with radiation and cisplatin significantly inhibited MG-63 cell proliferation compared with radiation or cisplatin treatment alone. Furthermore, radiation, cisplatin or the combined treatment with radiation and cisplatin increased the apoptosis rate of MG-63 cells, which resulted in G₂ phase arrest, and significantly decreased the migratory capacity of MG-63 cells. In addition, the apoptosis rate of MG-63 cells following combined radiation and cisplatin treatment was higher compared with the cisplatin group, but lower compared with the radiation group. Furthermore, combined treatment with radiation and cisplatin decreased the mRNA and protein expression levels of BRCA1 and p53. Additionally, combined treatment with radiation and cisplatin had a more potent inhibitory effect on p53 expression than on BRCA1 expression. In addition, combination of radiation and cisplatin had a higher inhibitory effect on Bax protein level and a higher inductive effect on Bcl-2 protein level compared with treatments with radiation and cisplatin alone. The results demonstrated that combined treatment of radiation and cisplatin exhibited superior therapeutic effects on osteosarcoma MG-63 cells compared with radiation or cisplatin treatment alone, which may be mediated by the BRCA1-p53 signaling pathway.

Metabolic markers of MG-63 osteosarcoma cell line response to doxorubicin and methotrexate treatment: comparison to cisplatin

A high resolution magic angle spinning NMR metabolomics study of the effects of doxorubicin (DOX), methotrexate (MTX) and cisplatin (cDDP) on MG-63 cells is presented and unveils the cellular metabolic adaptations to these drugs, often used together in clinical protocols. Although cDDP-treated cells were confirmed to undergo extensive membrane degradation accompanied by increased neutral lipids, DOX- and MTX-treated cells showed no lipids increase and different phospholipid signatures, which suggests that (i) DOX induces significant membrane degradation, decreased membrane synthesis, and apparent inhibition of de novo lipid synthesis, and (ii) MTX induces decreased membrane synthesis, while no membrane disruption or de novo lipid synthesis seem to occur. Nucleotide signatures were in apparent agreement with the different drug action mechanisms, a link having been found between UDP-GlcNAc and the active pathways of membrane degradation and energy metabolism, for cDDP and DOX, with a relation to oxidative state and DNA degradation, for cDDP. Correlation studies unveiled drug-specific antioxidative signatures, which pinpointed m- and s-inositols, taurine, glutamate/glutamine, and possibly creatine as important in glutathione metabolism. These results illustrate the ability of NMR metabolomics to measure cellular responses to different drugs, a first step toward understanding drug synergism and the definition of new biomarkers of drug efficacy.